Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Morgan Langille, University of Alberta
ClinicalTrials.gov Identifier:
NCT01111669
First received: September 15, 2009
Last updated: April 25, 2012
Last verified: April 2012

September 15, 2009
April 25, 2012
August 2009
December 2011   (final data collection date for primary outcome measure)
The Wormald grading scale, this is a validated instrument used to assess intraoperative bleeding during video endoscopy sinus surgery. [ Time Frame: Intraoperatively (as infusion of tranexamic acid or placebo is being infused) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01111669 on ClinicalTrials.gov Archive Site
  • Perioperative Sinus Endoscopy (POSE) scoring system, a systematic visualization evaluation of the sinuses [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Surgical time. [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Total blood loss (monitoring of suctioned blood and monitoring of sponges and throat packs used during the operation) [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Completeness of the surgical procedure as affected by bleeding. [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Number and types of any complications or adverse events [ Time Frame: Peri-operative period ] [ Designated as safety issue: Yes ]
  • Perioperative Sinus Endoscopy (POSE) scoring system, a systematic visualization evaluation of the sinuses [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Surgical time. [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Total blood loss (monitoring of suctioned blood and monitoring of sponges and throat packs used during the operation) [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Completeness of the surgical procedure as affected by bleeding. [ Time Frame: Intraoperatively ] [ Designated as safety issue: No ]
  • Number and types of complications and adverse events [ Time Frame: Peri-operative period ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery
Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery: A Double Blind Randomized Controlled Trial

Functional endoscopic sinus surgery (FESS) is an effective treatment of sinus disease. FESS is carried out using cameras to view the surgical field. Bleeding during the surgery can lead to poor surgical field visualization. Poor visualization has been associated with worse surgical outcomes. Tranexamic acid is a safe and effective agent used to achieve hemostasis during operative procedures. The current study is a randomized controlled trial in patients undergoing FESS to compare the effects of tranexamic acid versus placebo and the effects on surgical field visualization and adverse events.

Study Objectives: The current study will assess the effect of tranexamic acid on intraoperative bleeding and surgical outcomes during functional endoscopic sinus surgery.

Background: Tranexamic acid is an antifibrinolytic that prevents the activation of plasminogen to plasmin. Plasmin is responsible for the degradation of fibrin clots. This is the mechanism by which tranexamic acid prevents blood clot breakdown and reduces operative bleeding. Functional endoscopic sinus surgery, or FESS, is a widely used surgical technique to treat sinusitis and other diseases of the nose and nasal cavities. Bleeding during FESS can hinder surgical progress and has been associated with an increase in complications.

Methods: The current study is randomized, double-blind and placebo- controlled. Study sample size will be calculated based on a previous study of topical intranasal TA. Participants undergoing functional endoscopic sinus surgery will be recruited for the study during a preoperative outpatient clinic visit. Each participant will be randomized to a group receiving either tranexamic acid or normal saline bolus immediately prior to the operation. Inclusion criteria for the study are as follows: patients must be diagnosed with either 1. Chronic rhinosinusitis with polyposis (CRSwP) or 2. Chronic hyperplastic sinusitis. Patients must have an ASA classification of I or II and must be undergoing bilateral FESS as treatment for one of the above diagnoses. Exclusion criteria include patients with hypertension (treated or untreated), thrombotic diathesis, vascular disease, risk factors for vascular disease, colorblindness, renal failure, and those who may be pregnant. These exclusion criteria are based on the potential risks of using tranexamic acid in these patients (see safety data information section below). The exclusion criteria for hypertension will include anyone who has been diagnosed previously with hypertension or has been on anti-hypertensive medications for this diagnosis. The hypertensive patients will be excluded due to the difficulties maintaining standardized anesthesia protocol (such as mean arterial pressure) in these patients. The authors of the current study will not be testing for pregnancy. Patients will be asked the date of their last menstrual period as per the standard pre-operative questionnaire, any patients who may be pregnant would not only be excluded from the trial but would not undergo a general anesthetic for an elective procedure due to the risk of preterm labour. The diagnosis of renal failure will be determined by patient history, the current study will not require systematic lab diagnosis to calculate renal function. The study will keep a record of the surgeon(s) and residents present during surgery to evaluate potential differences during the data analysis. The study will blind both the surgeon(s) and anesthesiologist as to what each patient received. The day before a scheduled operation of a patient enrolled in the study, the pharmacy will determine if the patient is to receive TA or placebo based on the randomization table. The bolus of TA is prepared according to patient weight (15mg/kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg/kg per hour or TA preparation or normal saline for the duration of the operation. The current study will use a standardized anesthesia protocol using universally accepted parameters. The operation will be carried out using primarily inhalational anesthetic. End- tidal CO2 will be maintained between the target ranges of 30-35 mmHg. The head of the bed will be elevated to 15 degrees. The target range for the mean arterial pressure will be 60-70 mmHg.

Outcome Measures: The outcome measures for the current study are as follows: 1. The Wormald grading scale, this is a validated instrument used to assess intraoperative bleeding during video endoscopy sinus surgery. Dr. Wright will apply the Wormald grading scale intraoperatively. 2. Perioperative Sinus Endoscopy (POSE) scoring system, a systematic visualization evaluation of the sinuses. 3. Lund- Kennedy endoscopic reporting system, a validated staging system for sinus disease. 4. Lund- MacKay CT score, used for radiologic evaluation of sinus disease, 5. Number of sinuses and which sinuses were involved in the operative procedure. 6. Surgical time. 7. Total blood loss (monitoring of suctioned blood and monitoring of sponges and throat packs used during the operation. 8. Completeness of the surgical procedure as affected by bleeding.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Chronic Rhinosinusitis With Polyposis
  • Chronic Hyperplastic Sinusitis
  • Drug: Tranexamic Acid
    The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
    Other Name: cyklokapron
  • Drug: Normal Saline (placebo)
    The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
  • Experimental: Tranexamic Acid
    Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
    Intervention: Drug: Tranexamic Acid
  • Placebo Comparator: Normal Saline
    The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
    Intervention: Drug: Normal Saline (placebo)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must be diagnosed with either:

  1. Chronic rhinosinusitis with polyposis (CRSwP) or
  2. Chronic hyperplastic sinusitis. Patients must have an ASA classification of I or II and must be undergoing bilateral FESS as treatment for one of the above diagnoses.

Exclusion Criteria:

  1. Hypertension (treated or untreated)
  2. Thrombotic diathesis
  3. Vascular disease, risk factors for vascular disease,
  4. Colorblindness
  5. Renal failure
  6. Pregnancy
Both
17 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01111669
200901
No
Morgan Langille, University of Alberta
University of Alberta
Not Provided
Principal Investigator: Erin Wright, MD University of Alberta
University of Alberta
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP